Skip to main content
. Author manuscript; available in PMC: 2018 Jun 15.
Published in final edited form as: Clin Cancer Res. 2016 Dec 13;23(12):2942–2950. doi: 10.1158/1078-0432.CCR-16-1784

Figure 3. The effect of DS-8273a on populations of MDSC.

Figure 3

A. Selection of patients with elevated and control level of eMDSC and PMN-MDSC; B. The number of different population of MDSC during the treatment in patients with elevated pre-treatment level of PMN-MDSC; C. The number of monocytes and neutrophils during the treatment in patients with elevated pre-treatment level of PMN-MDSC; D. The number of MDSC in patients with control pre-treatment level of MDSC. E. Selection of patients with elevated and control level of M-MDSC; F. The number of different population of MDSC during the treatment in patients with elevated pre-treatment level of M-MDSC. In this figure *p<0.05, ** p<0.01 from values in healthy donors (HD).